uBiome, a microbial genetics company leveraging artificial intelligence to develop wellness products, clinical tests, and therapeutics based on the microbiome, today announced it has raised $83 million in Series C funding. The round was led by OS Fund, with participation from 8VC, Y Combinator, Dentsu Ventures, and additional new and existing investors. Now, uBiome is mining its database (the world's largest human microbiome database) to discover new therapeutic targets, with an initial focus on
Read More
Precision Therapeutics
Celsius Therapeutics Launches with $65M to Develop Precision Therapeutics for Autoimmune Disease & Cancer
Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key
Read More